Eli Lilly Acquires Engage Bio for Up to $202 Million
Eli Lilly acquires YC-backed Engage Biologics and its Tethosome non-viral DNA delivery platform for up to $202 million in cash.
Engage Bio
Potent, durable, and redosable non-viral genetic medicines
Founders
Will Olsen
CEO & Co-Founder
Funding History
Acquisition
$202M
May 2026
Led by Eli Lilly
Eli Lilly